Global Information
회사소개 | 문의 | 비교리스트

비뇨생식기용 치료제 시장 : 성장, 동향, 예측(2019-2024년)

Genitourinary Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence LLP
발행일 2019년 06월 상품 코드 871435
페이지 정보 영문
US $ 4,250 ₩ 5,134,000 PDF by E-mail (Single User License)
US $ 4,750 ₩ 5,738,000 PDF by E-mail (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,248,000 PDF by E-mail (Site License)
US $ 7,500 ₩ 9,060,000 PDF by E-mail (Corporate License)

비뇨생식기용 치료제 시장 : 성장, 동향, 예측(2019-2024년) Genitourinary Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 06월 페이지 정보 : 영문

세계의 비뇨생식기용 치료제(Genitourinary Drugs) 시장에 대해 조사했으며, 시장 개요와 성장 촉진요인·저해요인, 질병 종류·치료제 종류·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 정리했습니다.


제1장 서론

  • 연구 성과
  • 조사 가정
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 비뇨생식기 질환의 이환율 증가
    • 가처분 소득 증가와 의료 인프라의 지속적인 개선
    • 증가하는 파이프라인 제품
  • 시장 성장 저해요인
    • 치료 컴플라이언스의 결여
    • 위조 의약품 출현 증가
  • Porter’s Five Forces 분석
    • 신규 참여업체의 위협
    • 바이어/소비자의 협상력
    • 공급업체의 협상력
    • 대체 제품의 위협
    • 업계내의 경쟁

제5장 시장 세분화

  • 질병 종류별
    • 발기부전
    • 임질
    • 성기포진
    • 요로감염증
    • 요실금
    • 사구체신염
    • 만성신부전
    • 기타
  • 치료제 종류별
    • 조화요법(Harmonal Therapy)
    • 임포텐츠제(Impotence agents)
    • 자궁이완제
    • 진경제
    • 뇨pH조정제
    • 자궁자극제
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Company
    • GlaxoSmithKline
    • Achaogen, Inc.
    • Melinta Therapeutics, Inc
    • Wellstat Therapeutics Corporation
    • Allergan
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc

제7장 시장 기회 및 향후 동향

KSM 19.07.04

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Market Overview

Rise in the incidence of genitourinary diseases and infections has led to the growth of the genitourinary drugs market globally. Rising disposable incomes and constant improvements in healthcare infrastructure, increase in investments on R&D activities in developing novel molecules for the treatment of genitourinary diseases and increasing number of pipeline drugs are also driving the market in the forecast period. However, an increasing number of counterfeit drugs and lack of awareness about the infections and drugs for the treatment are going to restrain the market for Genitourinary Drugs.

Scope of the Report

Genitourinary tract agents are medicines, which are used to treat conditions of the reproductive organs and excretory system or urinary tract. The term "genitourinary" actually refers to two different systems. Urinary refers to the system responsible for removal of nitrogenous waste products of metabolism from the bloodstream, disposal of concentrated wastes (urine), and also water conservation. Genito refers to the genital organs and the reproductive system, which is responsible for the production of succeeding generations for the perpetuation of the species. The genitourinary (GU) system may be affected by congenital abnormalities, inflammation, infection, other body systems or diseases of the kidneys.

Key Market Trends

Urinary Tract Infections to dominate the Global Genitourinary Drugs Market

As there is an increase in the incidence of urinary tract infections, the demand for drugs increases which in turn is driving the global urinary tract infection therapeutics market. Furthermore, the launch of combination drugs, development, and approval of new drugs which are more efficient, and the increasing geriatric population are also expected to boost the growth of the urinary tract infection segment in Global Genitourinary Drugs Market. For instance, in August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug, which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam. December 2017: FDA accepted the review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) for June 2018.

The Asia Pacific is expected to be the fastest growing region

Asia is expected to experience a high growth rate in the genitourinary drugs market in the next few years due to rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases, increasing awareness about genitourinary diseases, rise in health care expenditure and developing health care infrastructure in the region. Growing demographics and economies in the developing countries, such as India and China, are expected to lead to the rise of the genitourinary drugs market in the Asia Pacific region.

Competitive Landscape

The global genitourinary drugs market displays high competition among market players. Major market players are investing high capitals on R&D and generating many strategies such as new product launches and developments, geographical expansions, collaborations and acquisitions to strengthen their market position in the global genitourinary drugs market. For instance, in September 2018: TherapeuticsMD, Inc. launched Imvexxy (estradiol vaginal inserts). for treatment of moderate-to-severe dyspareunia. Major Players in global genitourinary drugs market include Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline, Achaogen, Inc., Melinta Therapeutics, Inc, Wellstat Therapeutics Corporation, Allergan, Merck & Co., Inc., Novartis AG, and Pfizer, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Genitourinary Disorders
    • 4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure
    • 4.2.3 Increasing Pipeline Products
  • 4.3 Market Restraints
    • 4.3.1 Lack of Therapy Compliance
    • 4.3.2 Increasing Advent of Counterfeit Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disease Type
    • 5.1.1 Erectile dysfunction
    • 5.1.2 Gonorrhoea
    • 5.1.3 Genital Herpes
    • 5.1.4 Urinary Tract Infections
    • 5.1.5 Urinary Incontinence
    • 5.1.6 Glomerulonephritis
    • 5.1.7 Chronic renal failure
    • 5.1.8 Others
  • 5.2 By Drug Type
    • 5.2.1 Harmonal Therapy
    • 5.2.2 Impotence agents
    • 5.2.3 Uterine relaxants
    • 5.2.4 Urinary antispasmodics
    • 5.2.5 Urinary pH modifiers
    • 5.2.6 Uterine stimulants
    • 5.2.7 Miscellaneous genitourinary tract agents
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Bristol-Myers Squibb Co.
    • 6.1.2 Eli Lilly and Company
    • 6.1.3 GlaxoSmithKline
    • 6.1.4 Achaogen, Inc.
    • 6.1.5 Melinta Therapeutics, Inc
    • 6.1.6 Wellstat Therapeutics Corporation
    • 6.1.7 Allergan
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 Pfizer Inc


Back to Top
전화 문의